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Abstract
The Microphthalmia-associated transcription factor (MITF) is an important regulator of cell-type specific functions in
melanocytic cells. MITF is essential for the survival of pigmented cells, but whereas high levels of MITF drive melanocyte
differentiation, lower levels are required to permit proliferation and survival of melanoma cells. MITF is phosphorylated by
ERK, and this stimulates its activation, but also targets it for degradation through the ubiquitin-proteosome pathway,
coupling MITF degradation to its activation. We have previously shown that because ERK is hyper-activated in melanoma
cells in which BRAF is mutated, the MITF protein is constitutively down-regulated. Here we describe another intriguing
aspect of MITF regulation by oncogenic BRAF in melanoma cells. We show oncogenic BRAF up-regulates MITF transcription
through ERK and the transcription factor BRN2 (N-Oct3). In contrast, we show that in melanocytes this pathway does not
exist because BRN2 is not expressed, demonstrating that MITF regulation is a newly acquired function of oncogenic BRAF
that is not performed by the wild-type protein. Critically, in melanoma cells MITF is required downstream of oncogenic BRAF
because it regulates expression of key cell cycle regulatory proteins such as CDK2 and CDK4. Wild-type BRAF does not
regulate this pathway in melanocytes. Thus, we show that oncogenic BRAF exerts exquisite control over MITF on two levels.
It downregulates the protein by stimulating its degradation, but then counteracts this by increasing transcription through
BRN2. Our data suggest that oncogenic BRAF plays a critical role in regulating MITF expression to ensure that its protein
levels are compatible with proliferation and survival of melanoma cells. We propose that its ability to appropriate the
regulation of this critical factor explains in part why BRAF is such a potent oncogene in melanoma.
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Introduction
Human cancers arise through a multistage process, driven in
part by accumulated genetic aberrations that stimulate cancer cell
proliferation and survival [1]. Many of these changes, such as the
mutations that activate oncogenes, are restricted to particular cell
lineages and so are linked to particular types of cancer [2]. An
example of this is seen with BRAF, a serine/threonine specific
protein kinase that is mutated in 50–70% of spontaneous
cutaneous melanomas. The most common mutation in melanoma
(over 90% of cases) is a glutamic acid for valine substitution at
position 600 (V600E) [3].
V600EBRAF is activated almost 500 fold
[4], it transforms immortalised melanocytes [5], and it stimulates
proliferation and survival in melanoma cells [6,7].
V600EBRAF also
stimulates melanoma cell invasion in vitro and is important for
tumour neo-angiogenesis in vivo [8]. Furthermore, inhibition of
oncogenic BRAF induces tumour shrinkage in vivo [7,9]. These
findings show that oncogenic BRAF controls many aspects of
melanoma cell biology and yet it is currently unclear why BRAF is
such a potent oncogene in the melanocyte lineage.
Another protein that is important in melanoma is the basic helix-
loop-helix leucine zipper transcription factor MITF (microphthal-
mia-associated transcription factor). MITF is considered to be the
‘‘master regulator of melanocytes’’ because it is essential for
melanoblast survival and melanocyte lineage commitment. It
regulates expression of melanogenic enzymes such as tyrosinase
[10], and contributes to melanocyte differentiation by triggering cell
cycle exit throughinduction of the cell cycleinhibitorsp16
INK4a and
p21
Cip [11,12]. We have previously shown that the differentiation
functions of MITF occur at high protein concentrations, and
accordingly, high levels of MITF are anti-proliferative in melanoma
cells [13]. In agreement with this, low levels of MITF protein are
found in invasive melanoma cells [14] and are associated with poor
prognosis and disease progression in patients [15–17]. These data
suggest that MITF must be down-regulated for melanoma
progression and consistent with this, we have shown that in
melanoma cells oncogenic BRAF suppresses MITF protein levels
through ERK-mediated phosphorylation and degradation [13].
Despite all the evidence suggesting that MITF must be down-
regulated for melanoma progression, MITF expression is essential
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2734for proliferation and survival of melanoma cells because it
regulates genes such as CDK2 and BCL-2 respectively [18,19].
Furthermore, the MITF gene is amplified in 10–15% of
melanomas in which BRAF is mutated [20], supporting the view
that continued expression of MITF is essential in melanoma cells.
These observations show that the connection between MITF
and melanoma development is complex. They also suggest that the
interaction between oncogenic BRAF and MITF is more complex
than previously reported and this prompted us to examine the
interaction between these important proteins in more detail. Here
we describe a new aspect of MITF regulation by oncogenic BRAF.
We show that BRAF induces MITF transcription through the
MEK/ERK cascade and the transcription factor BRN2. Thus, we
propose that oncogenic BRAF down-regulates the MITF protein
by targeting it for degradation in an ERK-dependent manner, but
then counters this by stimulating MITF transcription in a BRN2-
dependent manner. Through these opposing mechanisms, onco-
genic BRAF executes exquisite control over MITF expression,
ensuring that the protein levels are permissive for melanoma cell
survival and proliferation.
Results
MITF expression is dependent on oncogenic BRAF in
melanoma cells
Previous studies have shown that ERK phosphorylates MITF
and targets it for degradation in a proteasome-dependent manner
[21,22]. We have gone on to show that as a consequence of ERK
being constitutively activated in melanoma cell lines expressing
oncogenic BRAF, MITF protein levels are lower in mutant BRAF
melanoma cells than in melanocytes ([13] and see Figure S1).
These data suggest that if ERK were inhibited in BRAF mutant
melanoma cells, MITF protein levels should increase. We tested
this using the MEK inhibitor U0126, which efficiently blocked
ERK activity in BRAF mutant melanoma cells (Figure 1A).
Notably, this resulted in a significant reduction in the proportion
of high molecular weight, phosphorylated forms of MITF in the
cells (Figure 1A, see *), but surprisingly long-term MEK/ERK
inhibition did not lead to an increase in MITF protein as expected,
but rather caused an almost complete loss of MITF expression
(Figure 1A). Thus, in apparent contradiction to our previous
findings, these data suggest that ERK activation is necessary for
MITF expression in melanoma cells expressing oncogenic BRAF.
To corroborate these findings, we used RNA interference
(RNAi) to deplete BRAF in melanoma cell lines. This caused the
expected reduction in ERK activity (Figure 1B) and in agreement
with the U0126 results described above, also caused a reduction in
MITF expression (Figure 1B). To ensure the results above were
not a post-extraction artefact, we used an immuno-fluorescence
approach, depleting BRAF with fluorescently-labelled siRNA
oligonucleotides and this also led to a substantial reduction in
nuclear MITF staining (Figure 1C). Furthermore, we found that
BRAF depletion resulted in reduced MITF mRNA expression in
melanoma cells (Figure 1D). Thus, although we have shown that
Figure 1. MITF expression requires BRAF in melanoma cells. A) Western blot for MITF, phosphorylated ERK (ppERK) and total ERK2 in
untreated (-) melanoma cells or in cells treated with DMSO (D) or U0126 (U0; 10 mM) for 48 h. B) Western blot for BRAF, MITF, ppERK and total ERK2 in
melanoma cells 48 h after transfection with control (SC) or BRAF (B1, B2) siRNAs. C) Immunohistochemistry analysis of WM266-4 cells transfected with
Alexa-Fluor-647-labelled control (SC) of BRAF siRNA probes (blue). Cells were stained for BRAF or MITF (red) after 48 h and DNA was stained using
SYTOXH-green (green). D) Quantitative RT-PCR analysis of MITF in A375 and WM266-4 cells 24 and 48 h after transfection with control (SC) or BRAF
(B1, B2) siRNA. MITF expression levels are expressed relative to the GAPDH control.
doi:10.1371/journal.pone.0002734.g001
BRAF Induces MITF Expression
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stimulating its degradation through the ubiquitin pathway [13],
the data presented here show that this pathway is also required for
MITF mRNA expression in these cells. Together these data
suggest that
V600EBRAF regulates MITF at both the mRNA level
and the protein level, so we further examined the role played by
BRAF in the regulation of MITF transcription.
BRAF regulates MITF transcription through BRN2
First, we examined MITF promoter activity using a luciferase
reporter construct. We show that BRAF depletion caused a
substantial decrease in the activity of the MITF promoter in
melanoma cells (Figure 2A). Conversely,
V600EBRAF over-expres-
sion activated theMITFpromoter,whereaswild-typeBRAFdidnot
(Figure 2B). We mapped the
V600EBRAF-responsive element(s) to a
promoter fragment of 293 to +120 relative to the transcription start
site (Figure 2C). This promoter fragment does not contain any
elements previously characterized as being important for MITF
promoter activity in melanocytic cells ([10] and see Figure 2C). In
silico analysis of this fragment (http://www.cbrc.jp/research/db/
TFSEARCH.html) revealed a putative binding site for the POU-
domain transcription factor BRN2 at 250 to 236 relative to the
transcription start site (Figure 2D), so we investigated the role of
BRN2 in MITF regulation in melanoma cells.
BRN2 bound to a fragment (277 to 220) of the MITF
promoter in vitro, but not when the putative BRN2 binding site was
mutated (data not shown) and chromatin immunoprecipitation
(ChIP) assays showed that endogenous BRN2 binds to the
proximal region of the MITF promoter in melanoma cells
(Figure 2E). We used the 2333 MITF promoter fragment
(Figure 2C) for further analysis because it contains all of the
elements previously shown to be relevant to MITF regulation in
melanocytic cells [10]. BRN2 activated the 2333 promoter
(Figure 2F), but this activation was significantly reduced when the
59 or 39 region the BRN2 element was mutated (mut1, mut2;
Figures 2D and 2F). Importantly, the ability of
V600EBRAF to
activate the MITF promoter was also dramatically reduced when
the BRN2 element was mutated (Figure 2F). This suggested that
BRN2 acts downstream of BRAF and in agreement with this
hypothesis the
V600EBRAF-stimulated activation of the MITF
promoter was strongly suppressed when endogenous BRN2 was
depleted (Figure 2G).
BRN2 is required for MITF expression in human
melanoma cells
The data above place BRN2 between
V600EBRAF and MITF in
melanoma cells and this is consistent with our previous study
showing that BRN2 is downstream of
V600EBRAF [23]. Here we
confirm that BRN2 expression is dependent on ERK signalling
downstream of oncogenic BRAF in melanoma cells (Figure 3A).
Furthermore, depletion of endogenous BRN2 reduced the levels of
endogenous MITF protein in all melanoma cell lines in which
BRAF is mutated (Figure 3B). The decrease in MITF protein was
due to reduced MITF mRNA expression as determined by
quantitative RT-PCR (Figure 3C) and together these findings
clearly demonstrate that in melanoma cells BRN2 is required for
MITF expression downstream of oncogenic BRAF.
Importantly, we show that BRN2 and MITF expression are
strongly correlated with the presence of BRAF mutations in
human melanoma samples (Figure 3D). These data link mutant
BRAF to BRN2 and MITF expression in clinical samples,
suggesting that this pathway is essential for progression of
BRAF-driven melanomas.
MITF regulates the cell cycle downstream of
V600EBRAF in
melanoma cells
Previous studies have shown that
V600EBRAF stimulates
melanoma cell proliferation [6,7] and here we show that MITF is
required for proliferation in these cells, because MITF depletion
blocks DNA synthesis in BRAF mutant melanoma cells (Figure 4A).
Commensurate with their roles in proliferation, depletion of BRAF
or MITF caused substantial down-regulation of the cell cycle
regulators CDK4, CDK2 and p21
Cip1 (Figure 4B). CDK2 and
p21
Cip1 are previously identified MITF target genes in melanoma
cells [12,24] and our data suggest that the melanoma susceptibility
gene CDK4 is also an MITF target gene (see also Figure S2).
Importantly, MITF depletion in melanoma cells blocked CDK2,
p21
Cip1 and CDK4 expression even though ERK was not inhibited
(Figure 4B). Thus we show that not only is MITF regulated by ERK
but also that it functions downstream of this signalling pathway. In
agreement with this, CDK2 expression was restored when an
oestrogen-regulated version of MITF [12,13] was expressed and
activated in cells in which BRAF was depleted (Figure 4C; see
Figure 1A for degree of BRAF depletion). Furthermore, CDK2 and
CDK4 expression was also restored when full-length MITF was re-
expressed in BRAF depleted cells (Figure 4D and Figure S3) and
importantly, this occurred in the absence of ERK reactivation
(Figure 4D, lane 4). Critically, MITF re-expression rescued
proliferation of melanoma cells when BRAF was depleted using
RNAi (Figure 4E), or when MEK was inhibited with PD184352
(Figure 4F). These data show that MITF regulates the expression of
critical cell cycle regulatory proteins and stimulates melanoma cell
proliferation downstream of BRAF in melanoma cells.
V600EBRAF, but not
WTBRAF regulates MITF expression in
melanocytes
We next examined the interaction between
WTBRAF and
MITF in normal human melanocytes. As in melanoma cells,
BRAF and MITF are both essential for melanocyte proliferation
(Figure 5A), but in contrast to melanoma cells, MITF expression
does not depend on BRAF expression (Figure 5B) or MEK/ERK
signalling (Figure 5C) in melanocytes. This is reflected by a
functional independence between BRAF and MITF in melano-
cytes. Whereas MITF depletion caused down-regulation of
CDK4, CDK2 and p21
Cip1 in melanocytes, these proteins were
not down-regulated when
WTBRAF was depleted (Figure 5D).
One possible explanation for the lack of MITF regulation by
WTBRAF is that unlike melanoma cells, melanocytes do not express
BRN2 (Figure 5E). Notably, whereas
V600EBRAF can induce BRN2
expression in melanocytes,
WTBRAF does not stimulate BRN2
expression in these cells (Figure 5F). Importantly, when introduced
into melanocytes,both
V600EBRAF and BRN2can activate the MITF
promoter (Figure 5G). Thus in melanocytes although
WTBRAF does
not regulate MITF,
V600EBRAF can induce expression of BRN2,
allowing it to induce MITF transcription. Notably, the induction of
BRN2 through MEK and ERK in melanoma cells appears to be
fundamental to the ability of
V600EBRAF to regulate MITF in these
cells (Figure 3A). Thus, we have established that in addition to
regulating MITF at the protein level [13], oncogenic BRAF also
regulates MITF at the level of gene transcription in melanocytic cells.
Discussion
In this study, we show that
V600EBRAF regulates the MITF
promoter through the octamer-binding transcription factor BRN2
(N-Oct-3). BRN2 is a neuronal-specific protein that is expressed in
developing melanoblasts, but which becomes down-regulated as
these cells differentiate into melanocytes [25]. Importantly, BRN2
BRAF Induces MITF Expression
PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2734Figure 2. BRAF regulates the MITF promoter through BRN2. A) MITF (22293 to +120) promoter activity in A375 cells transfected with control
(SC) or BRAF (B1, B2) siRNA. Extracts were prepared after 48 h and analysed for BRAF and ERK2 (loading control) by Western blotting and for luciferase
activity [RLU]. B) MITF (22293 to +120) promoter activity in A375 cells transfected with the indicated amounts (50–500 ng) of myc-tagged
V600EBRAF,
myc-tagged
WTBRAF or an empty vector control (vec). Extracts, prepared 48 h after transfection were analysed for expression of myc-tagged BRAF (*:
non-specific band), ERK2 (loading control) by Western blot and for luciferase activity [RLU]. C) MITF promoter activity induced by
V600EBRAF. Cells were
transfected with the indicated promoter fragments and the fold induction stimulated by
V600EBRAF is indicated. Binding sites previously identified in
the MITF promoter are indicated [10]. D) The sequence of the MITF promoter from 253 to 227, with the putative BRN2 binding site indicated. The
binding site mutations (mut 1 and mut 2) are also shown. E) Chromatin immunoprecipitation (ChIP) assays from A375 cells using BRN2 antibodies,
non-specific antibodies (IgG) or no antibody (no Ab). The 2170 to +120 region of the MITF promoter was amplified, and as a control the cyclin D1
promoter was also analysed. F) The activity of the 2333 luciferase reporter, stimulated by
V600EBRAF or BRN2 in A375 cells is shown. The effects of the
BRN2 binding site mutations (mut 1, mut 2) are shown, relative (% Activity) to the activity of the non-mutated promoter. G) The activity of the 2333
luciferase promoter in A375 cells transfected with control (SC) or BRN2 siRNA is shown. The cells were transfected with
V600EBRAF and the reporter
construct 24 h after the siRNA had been introduced. Luciferase activity was measured after a further 48 h.
doi:10.1371/journal.pone.0002734.g002
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proliferation and tumourigenesis [26]. Thus BRN2 re-expression
is important for melanoma progression and we have previously
shown that BRN2 is a target of oncogenic BRAF in melanoma
cells [23]. Here we show that BRN2 expression can also be
induced by oncogenic BRAF in melanocytes (Figure 5F). We
further demonstrate that BRN2 induces MITF transcription
through a binding site located at 250/236 of the MITF
promoter, linking MITF expression to oncogenic BRAF through
BRN2. Consistent with this, we show that BRN2 and MITF
expression occur coincident with oncogenic BRAF in human
melanoma samples (Figure 3D). Importantly, we show that wild
type BRAF does not induce BRN2 expression in melanocytes, and
neither does it stimulate MITF transcription in melanocytes or
melanoma cells. Together, these data show that the ability of
BRAF to regulate MITF expression is a newly acquired function of
the oncogenic protein and that this is mediated through its ability
to induce expression of BRN2.
Importantly, we previously reported that
V600EBRAF suppresses
theendogenousmitf promoter inmousemelanocytes[13]. Inlinewith
this, we find that
V600EBRAF also suppresses the promoter when
expressed in mouse melanoma cells (B16 cells, Figure S4). This
suggests that the MITF promoter is regulated differently by
oncogenic BRAF in mouse and human cells, but it should be
mentioned that in contrast to humans, somatic mutations in BRAF
do not appear to be a feature of mouse melanomas. Interestingly, we
find that like
V600EBRAF, BRN2 suppresses the MITF promoter in
mousecells(notshown),suggestingthatinmousecellsthepresenceor
absence of certain co-factors might modulate the outcome of the
action of BRN2on the MITF promoter.In summary, we have shown
that BRN2 induces MITF mRNA expression in human melanoma
cells and that through BRN2,
V600EBRAF can stimulate transcription
of the MITF gene in both melanoma cells and melanocytes.
It has previously been shown that MITF activation and
degradation are coupled because ERK phosphorylation both
activates MITF and targets it for degradation through the ubiquitin
pathway [21,22]. Importantly, we demonstrated that because ERK is
constitutively activated in BRAF mutant melanoma cells, MITF is
constantly degraded ([13] and see Figure S5), a finding that is in
agreement with the observation that MITF protein levels are
generally lower in BRAF mutant melanoma cell lines than in
primary melanocytes (Figure S1). Thus, our demonstration here that
V600EBRAF induces MITF transcription appears at first to be
counter-intuitive. However, MITF plays a critical role in pigment cell
behaviour and as previously described, this is partly controlled by the
level of MITF in the cells ([13] and see [27]). High levels of MITF
trigger cell cycle arrest and differentiation, whereas low levels of
activity trigger cell cycle arrest and death (see Figure 6). Thus, MITF
has both tumour promoting and tumour inhibitory activities [10] and
its ability to control cell fate decisions appears to depend on it levels of
expression [13] or possibly its levels of activity [27].
Thus MITF is akin to TGFb, which, is also either a tumour
promoter or a tumour suppressor [28] and we propose that MITF
expression/activity must be carefully regulated in melanoma cells
to ensure that the levels are not so low as to cause cell death but
equally, not so high as to cause cell cycle arrest and differentiation
(Figure 6). Our data suggest that oncogenic BRAF plays a key role
in regulating MITF to ensure that this is achieved and together
with our previous observations, these studies demonstrate that the
regulation of MITF by oncogenic BRAF is complex and
multifaceted. We posit that because constitutively active ERK is
so efficient at down-regulating MITF in BRAF mutant melanoma
cells, it is necessary for the cells to rescue MITF expression to
ensure that they can continue to proliferate and survive (Figure 6).
One strategy that the cells use to achieve this is the activation of
the MITF promoter by
V600EBRAF/ERK/BRN2 as described
here. Another strategy appears to be gene amplification, since the
MITF gene is amplified in approximately 15% of melanoma cases
Figure 3. BRN2 is required for MITF expression in melanoma
cells. A) Western blot for BRN2, ppERK and tubulin (loading control) in
WM266-4 cells treated with control (SC), BRAF or ERK2 siRNA. B)
Western blot for MITF, BRN2 and total ERK2 (loading control) in the
indicated melanoma cells treated with control (SC) or BRN2 siRNA. C)
Quantitative real time PCR of MITF mRNA expression in the indicated
melanoma cells treated with control (SC) or BRN2 siRNA. MITF
expression was normalised to GAPDH expression and is shown as fold
expression in reference to SC transfected cells. Results are for one
experiment assayed in triplicate. Similar results were obtained in three
independent experiments. D) Western blot for BRN2, MITF and total
ERK2 (loading control) in human melanoma samples expressing wild-
type BRAF (WT) or
V600EBRAF (VE). The expression of BRN2 and MITF
relative to ERK2 expression is indicated below the blots.
doi:10.1371/journal.pone.0002734.g003
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PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2734Figure 4. MITF acts downstream of BRAF in melanoma cells. A) DNA synthesis ([
3H]-thymidine incorporation) in SKMel28, A375 and WM266-4
cells 48–60 h after transfection with control (SC) or MITF (MI, MI1, MI3) siRNA. B) Western blot for BRAF, MITF, ppERK, CDK4, CDK2, p21
Cip (p21) and
total ERK2 (loading control) in WM266-4 and A375 cells 24 h and 48 h after transfection with control (SC), BRAF (B1) or MITF (MI, MI1, MI3) siRNA. C)
Expression of CDK2 in A375 cells transfected with Alexa-Fluor-647-labelled control (SC) or BRAF siRNA (blue). The cells were microinjected with
expression constructs for HA-tagged 4OHT-binding domain of the estrogen receptor (ER) or HA-tagged ER:MITF after 24 hours (green). The cells were
treated with 200 nM 4OHT and fixed and stained for CDK2 (red) after a further 40 h. D) Western blot for BRAF, MITF, CDK4, CDK2, ppERK and ERK in
A375 cells transfected with control (SC) or BRAF (B1) siRNAs, together with an empty vector (vec) or MITF expression construct (rescue). E) DNA
synthesis ([
3H]-thymidine incorporation) in A375 cells 40 h after transfection with control (SC) or BRAF (B1) siRNA, together with either an empty
vector (vec) or MITF expression construct (rescue). The levels of BRAF expressions are shown on a Western blot with ERK2 serving as the loading
control. F) Colony formation assay of SKMel28 cells infected with empty vector (pBabe) or MITF expression construct, and treated with 1 mM
PD184352 for 4 weeks. Whole plate and high-magnification images are shown. The inhibitory effect of PD184352 on ERK phosphorylation is shown
on a Western blot and actin was used as the loading control.
doi:10.1371/journal.pone.0002734.g004
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are not mutually exclusive because although MITF is amplified in
SKMel-28 cells [20], MITF expression still depends on oncogenic
BRAF in these cells (see Figure 1B).
In summary, we show that oncogenic BRAF plays a critical role
in regulating MITF expression in melanoma cells, using
apparently opposing mechanisms to exquisitely regulate the levels
of this critical transcription factor. This ensures that the levels of
MITF are optimal for tumour progression and suggests one reason
for why BRAF is such a potent oncogene in human melanoma.
Materials and Methods
Cell biology approaches
Culture and transfection and in vitro analysis of melanoma cell
lines, human melanocytes, stable melanocyte lines and the MITF
siRNA MI have been described [5]. Further siRNA oligonucleotides
were. For BRAF: B1: AGAAUUGGAUCUGGAUCAU; B2:
CAGUCUACAAGGGAAAGUG, for BRN2: BRN2-1: GCGCA-
GAGCCUGGUGCAGGUU; BRN2-2: CCGCAGCGUCUAAC-
CACUAUU; for MI1: GAACGAAGAAGAAGAUUUA; for MI3:
GACCUAACCUGUACAACAA for ERK2: CUCCAAAGCU-
CUGGACUUAUU. U0126 was from Promega. For thymidine
incorporation cells were incubated with
3H-thymidine (0.4 mCi/ml)
for 4 h before analysis. For the MEK inhibition rescue, 10
6 SKMel-
28 cells were infected with pBABEpuro or pBABEpuro-MITF
viruses, selected with 2 mg/ml puromycin for 48 hours and 5610
4 of
the remaining cells were plated in 10 cm dishes and incubated with
1 mM PD184352 for 4 weeks before being fixed, stained and
photographed. The antibodies used were: MITF: C5 and D5
(Neomarkers and generously provided by D. Fisher); BRAF: F-7;
Santa Cruz; phospho-ERK: MAPK-YT (Sigma); anti-myc (Abcam);
E R K 2 :C - 1 4( S a n t aC r u z ) ;C D K 2 :M 2( S a n t aC r u z ) ;C D K 4 :C - 2 2
(Santa Cruz); BRN2: C-20 (Santa Cruz); p21 (TDL).
Immunofluorescence
Fixed cells transfected with Alexa-Fluor-647-labelled siRNA
probes were incubated with the appropriate primary and Cy3-
conjugated secondary antibodies (Dianova). Nuclei were counter-
Figure 5.
V600EBRAF can regulate MITF expression in melanocytes. A) Thymidine incorporation in normal melanocytes 40 h after transfection
with control (SC), BRAF (B1) or MITF siRNA. B) Western blot for BRAF, MITF and ERK2 (loading control) in normal human melanocytes 48 h after
transfection with control (SC) or BRAF (B1) siRNA. C) Western blot for MITF, ppERK and ERK2 (loading control) in normal human melanocytes 24 h
after treatment with DMSO (D) or U0126 (U0; 10 mM). D) Western blot for CDK4, CDK2, p21
Cip (p21) and ERK2 (loading control) in human melanocytes
48 h after transfection with control (SC), BRAF (B1) or MITF (MI) siRNA. E) Western blot for BRN2 and total ERK2 (loading control) in Hela cells (negative
control), human melanocytes and the indicated melanoma cell lines carrying mutant BRAF. F) Western blot for BRN2, ppERK and total ERK2 (loading
control) in melanocytes transfected with empty vector (control),
WTBRAF or
V600EBRAF. G) MITF (22293 to +120) promoter-reporter (luciferase) activity
in melanocytes transfected with an empty vector (vec), or with a BRN2 or
V600EBRAF expression construct.
doi:10.1371/journal.pone.0002734.g005
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detected with fluorescein-coupled anti-HA antibody 3F10 (Roche).
Reverse transcriptate-PCR and Chromatin-
immunoprecipitation
RNA was isolated with TRIZOLH a n ds e l e c t e dg e n e sw e r e
amplified by quantitative real time PCR using SYBR green (Qiagen).
Primers sequences were MITF: CCGTCTCTCACTGGATTGGT,
TACTTGGTGGGGTTTTCGAG; GAPDH: CAATGACCCC-
TTCATTGACC, GACAAGCTTCCCGTTCTCAG. Chromatin immuno-
precipitation (ChIP) assays were performed with IMGENEX reagents as
recommended. Primer sequences were MITF promoter: CGTCACT-
TAAAAAGGTACCTTTATATTTATG, TGTTTTAGCTAG-
CACCAATCCAGTGAGAGACGG; cyclin D1 promoter: AA-
CAAAACCAATTAGGAACCTT, ATTTCCTTCATCTTGTCCTTCT.
Luciferase Reporter Constructs and Assays
BRAF and
V600EBRAF expression constructs are described and
BRN2 was expressed using pEFPlink.6 [4]. Approximately 2.3 kb of
the MITF promoter (22293 to +120) and the various truncated
promoters were cloned into pGL2 (Promega). Mutant promoter
constructs (mut1, mut2) were generated by PCR directed mutagen-
esis. Cells were transfected with 0.6 mg of the indicated promoter-
reporter constructs, 0.3 mgo fB R A F ,
V600EBRAF or BRN2
expression constructs and 0.3 mg of pSV-ß-Galactosidase (Promega)
using Lipofectamine (Gibco). Cells were analysed for luciferase
activity after 48 h using RLB buffer (Promega). The data were
corrected for b-galactosidase and represent the activity for assays
performed in triplicate, with error bars to represent standard
deviations from the mean. All experiments were performed a
minimum of 3 times.
Supporting Information
Figure S1 Melanoma cells express lower levels of MITF than
melanocytes. Human melanocytes and melanoma cells expressing
oncogenic BRAF were analysed for MITF expression. ERK2
served as loading control.
Found at: doi:10.1371/journal.pone.0002734.s001 (0.24 MB TIF)
Figure S2 MITF regulates CDK2 and CDK4 transcription.
CDK4 expression is regulated by MITF in melanoma cells. (A) RT-
PCR for CDK4 and CDK2 (control) in A375 and WM266-4 cells
transfected with either control (SC) or MITF (MI) siRNAs. Cells
were analysed 24 and 48 hours after transfection and GAPDH
serves as a loading control. (B) Real-time RT-PCR for CDK4 in
A375 and WM266-4 cells transfected with either control (SC) or
MITF (MI) siRNAs. Cells were analysed 24 and 48 hours after
transfection. CDK4 expression is shown as fold expression in
referenceto SC transfected cellsand relativeto GAPDH expression.
Found at: doi:10.1371/journal.pone.0002734.s002 (0.47 MB TIF)
Figure S3 MITF regulates CDK2 and CDK4 transcription
downstream of oncogenic BRAF. Quantification of CDK2 and
CDK4 expresssion. A375 cells transfected with control (SC) or
BRAF (B1) siRNAs, together with an empty vector (vec) or an
MITF expression construct (rescue) were analysed for CDK2 and
CDK4 and the expression was quantified using ImageQuant
(Amersham, GE-Healthcare).
Found at: doi:10.1371/journal.pone.0002734.s003 (0.24 MB TIF)
Figure S4 Oncogenic BRAF suppresses the MITF promoter in
mouse melanoma cells. V600EBRAF suppresses the MITF promoter
in mouse melanoma cells. (A) Luciferase assay for the mouse MITF
promoter activity in B16 cells transfected with vector (vec) or
V600EBRAF as indicated. The cells were analysed 48 h after
transfection. (B) Luciferase assay for the human MITF promoter
activity in B16 cells transfected with vector (vec) or V600EBRAF as
indicated.
Found at: doi:10.1371/journal.pone.0002734.s004 (0.35 MB TIF)
Figure S5 Oncogenic BRAF suppresses MITF protein expres-
sion. Oncogenic BRAF suppresses MITF protein levels. Western
blot of human melanocytes transfected with V600EBRAF or an
empty vector. Cells were analysed for myc-tagged V600EBRAF,
MITF and ppERK. ERK2 was used as loading control.
Found at: doi:10.1371/journal.pone.0002734.s005 (0.21 MB TIF)
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